Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500
Best digital wallets for managing Indian blockchain assets  - Maximize Returns with ₹500

Best digital wallets for managing Indian blockchain assets - Maximize Returns with ₹500

₹1478

Best digital wallets for managing Indian blockchain assets ✌️【Career Goals】✌️Make your ₹500 grow rapidly with AI-backed investments.

quantity
Add to Wishlist
Product Description

Best digital wallets for managing Indian blockchain assets ✌️【Career Goals】✌️Make your ₹500 grow rapidly with AI-backed investments.

Best digital wallets for managing Indian blockchain assets ✌️【Career Goals】✌️Make your ₹500 grow rapidly with AI-backed investments.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

Best digital wallets for managing Indian blockchain assets ✌️【Career Goals】✌️From ₹500 to exponential growth. Start investing now for high returns!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

Best digital wallets for managing Indian blockchain assets ✌️【Career Goals】✌️Invest ₹500 and see your money grow with fast, reliable returns!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

Best digital wallets for managing Indian blockchain assets ✌️【Career Goals】✌️Start with ₹500 and earn big! High returns, low risk, and consistent growth.The underperformance persists despite a 22.Best digital wallets for managing Indian blockchain assets Diversify Your Portfolio with Smart Investments

Related Products